Goretti Duran
Research Subjects
Goretti Duran has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- María Jesús Lamas
Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
11 shared publications - Angel Carracedo
Grupo de Medicina Xenómica, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
10 shared publications - Beatriz Bernardez
Departament of Medicine and Pharmacology Group, University of Santiago de Compostela, Santiago de Compostela, Spain
5 shared publications - Francisco Barros-Angueira
Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain
4 shared publications Emilia Balboa
Genomics Medicine Group, Galician Public Foundation of Genomic Medicine (FPGMX), Santiago de Compostela, Spain
3 shared publicationsFrancisco Barros
Genomics Medicine Group, Galician Public Foundation of Genomic Medicine (FPGMX), Santiago de Compostela, Spain
3 shared publications
Latest Publications
- 26 July 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 88 (5) , 813-823
Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy
Purpose Genetic variants in genes involved in the distribution, metabolism, accumulation or repair of lesions are likely to influence the response of drugs used in the treatment of Head and Neck Cancer (HNC). We examine the effect of 36 SNPs on clinical outcomes in patients with locally advanced HNC who were receiving platinum-based chemoradiotherapy (CRT). Methods These SNPs were genotyped in 110 patients using the iPLEX Gold assay on the MassARRAY method in blood DNA samples and used Kaplan–Meier and Cox regression analyses to compare genotype groups with the survival. Results Two SNPs, rs717620 (ABCC2) and rs12934241 (MMP2) were strongly associated with overall survival (OS) and disease-free survival (DFS). At a median follow-up of 64.4 months, the allele A of rs717620 (ABCC2) had an increased risk of disease progression {hazard ratio [HR] = 1.79, p = 0.0018} and death (HR = 2.0, p = 0.00027). ABCC2 was associated with OS after a Bonferroni adjustment for multiple testing. The MMP2 rs12934241‐T allele was associated with an increased risk of worse OS and DFS (p = 0.0098 and p = 0.0015, respectively). One SNP of ABCB1 and three SNPs located in the ERCC2 gene showed an association with response in the subgroup of HNC patients treated with definitive CRT. Conclusions Our findings highlight the potential usefulness of SNPs in different genes involved in drug metabolism and repair DNA to predict the response and survival to CRT. ABCC2 is a potential predictor of OS in patients with HNC.
- 26 July 2021
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 88 (5) , 813-823
Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy
Purpose Genetic variants in genes involved in the distribution, metabolism, accumulation or repair of lesions are likely to influence the response of drugs used in the treatment of Head and Neck Cancer (HNC). We examine the effect of 36 SNPs on clinical outcomes in patients with locally advanced HNC who were receiving platinum-based chemoradiotherapy (CRT). Methods These SNPs were genotyped in 110 patients using the iPLEX Gold assay on the MassARRAY method in blood DNA samples and used Kaplan–Meier and Cox regression analyses to compare genotype groups with the survival. Results Two SNPs, rs717620 (ABCC2) and rs12934241 (MMP2) were strongly associated with overall survival (OS) and disease-free survival (DFS). At a median follow-up of 64.4 months, the allele A of rs717620 (ABCC2) had an increased risk of disease progression {hazard ratio [HR] = 1.79, p = 0.0018} and death (HR = 2.0, p = 0.00027). ABCC2 was associated with OS after a Bonferroni adjustment for multiple testing. The MMP2 rs12934241‐T allele was associated with an increased risk of worse OS and DFS (p = 0.0098 and p = 0.0015, respectively). One SNP of ABCB1 and three SNPs located in the ERCC2 gene showed an association with response in the subgroup of HNC patients treated with definitive CRT. Conclusions Our findings highlight the potential usefulness of SNPs in different genes involved in drug metabolism and repair DNA to predict the response and survival to CRT. ABCC2 is a potential predictor of OS in patients with HNC.
- 22 May 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 32 (6) , 310-322
Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
We studied the predictive value for response and toxicity of functional polymorphisms in genes involved in the oxaliplatin/fluorouracil pathway in colorectal cancer patients. One hundred and twenty-seven (127) patients were treated with curative intended surgery followed by adjuvant chemotherapy with FOLFOX (fluorouracil, leucovorin and oxaliplatin) regimen. The median age was 65.53 (27–80) years (66.9% male, 59.1% rectum). The median follow-up was 8.5 years (IQR, 4.1–9.4). At the end of follow-up, 59 patients (46.5%) had relapsed or died in the whole study population. We did find that XRCC1GG genotype is associated with a higher risk of developing haematologic toxicity. Furthermore, we report a significant association of the TS 3′UTR 6 bp/6 bp polymorphism and the XRCC1 rs25487 with a higher risk of developing anaemia and diarrhoea, respectively. On the other hand, none of the studied polymorphisms showed clinically relevant association with disease-free survival and overall survival or early failure to adjuvant FOLFOX therapy.
- 22 May 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 32 (6) , 310-322
Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
We studied the predictive value for response and toxicity of functional polymorphisms in genes involved in the oxaliplatin/fluorouracil pathway in colorectal cancer patients. One hundred and twenty-seven (127) patients were treated with curative intended surgery followed by adjuvant chemotherapy with FOLFOX (fluorouracil, leucovorin and oxaliplatin) regimen. The median age was 65.53 (27–80) years (66.9% male, 59.1% rectum). The median follow-up was 8.5 years (IQR, 4.1–9.4). At the end of follow-up, 59 patients (46.5%) had relapsed or died in the whole study population. We did find that XRCC1GG genotype is associated with a higher risk of developing haematologic toxicity. Furthermore, we report a significant association of the TS 3′UTR 6 bp/6 bp polymorphism and the XRCC1 rs25487 with a higher risk of developing anaemia and diarrhoea, respectively. On the other hand, none of the studied polymorphisms showed clinically relevant association with disease-free survival and overall survival or early failure to adjuvant FOLFOX therapy.
- 29 November 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (1) , 17-25
Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study
Background: Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure.Objective: To show the association between subtherapeutic voriconazole concentrations and factors affecting voriconazole pharmacokinetics: CYP2C19 genotype and drug–drug interactions.Methods: Adults receiving voriconazole for antifungal treatment or prophylaxis were included in a multicenter prospective study conducted in Spain. The prevalence of subtherapeutic voriconazole troughs was analyzed in the rapid metabolizer and ultra‐rapid metabolizer patients (RMs and UMs, respectively), and compared with the rest of the patients. The relationship between voriconazole concentration, CYP2C19 phenotype, adverse events (AEs), and drug–drug interactions was also assessed.Results: In this study 78 patients were included with a wide variability in voriconazole plasma levels with only 44.8% of patients attaining trough concentrations within the therapeutic range of 1 and 5.5 µg/ml. The allele frequency of *17 variant was found to be 29.5%. Compared with patients with other phenotypes, RMs and UMs had a lower voriconazole plasma concentration (RM/UM: 1.85 ± 0.24 µg/ml vs other phenotypes: 2.36 ± 0.26 µg/ml). Adverse events were more common in patients with higher voriconazole concentrations (pCYP2C19 genotype‐guided voriconazole dosing to achieve concentrations in the therapeutic range in the early course of therapy. Larger studies are needed to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics.
- 29 November 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (1) , 17-25
Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study
Background: Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure.Objective: To show the association between subtherapeutic voriconazole concentrations and factors affecting voriconazole pharmacokinetics: CYP2C19 genotype and drug–drug interactions.Methods: Adults receiving voriconazole for antifungal treatment or prophylaxis were included in a multicenter prospective study conducted in Spain. The prevalence of subtherapeutic voriconazole troughs was analyzed in the rapid metabolizer and ultra‐rapid metabolizer patients (RMs and UMs, respectively), and compared with the rest of the patients. The relationship between voriconazole concentration, CYP2C19 phenotype, adverse events (AEs), and drug–drug interactions was also assessed.Results: In this study 78 patients were included with a wide variability in voriconazole plasma levels with only 44.8% of patients attaining trough concentrations within the therapeutic range of 1 and 5.5 µg/ml. The allele frequency of *17 variant was found to be 29.5%. Compared with patients with other phenotypes, RMs and UMs had a lower voriconazole plasma concentration (RM/UM: 1.85 ± 0.24 µg/ml vs other phenotypes: 2.36 ± 0.26 µg/ml). Adverse events were more common in patients with higher voriconazole concentrations (pCYP2C19 genotype‐guided voriconazole dosing to achieve concentrations in the therapeutic range in the early course of therapy. Larger studies are needed to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics.
- 11 April 2019
- Published by Wiley in Head & Neck
- Vol. 41 (8) , 2704-2715
Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum‐based chemoradiotherapy treatment
Background: Platinum‐based chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck squamous‐cell carcinomas (HNSCC), and most patients experience serious toxicities. The aim of this study was to investigate the association between candidate genes involved in radiation/platinum pathways and acute toxicity of CRT to determine the predictive value of these polymorphisms for toxicity.Methods: Thirty‐six selected single nucleotide polymorphisms (SNPs) in 29 genes were genotyped in 110 patients treated with cisplatin‐based CRT. DNA was obtained from blood samples, and SNP analysis was performed using a MassARRAY iPLEX Gold (Sequenom) method.Results: Patients with ERCC1 rs11615‐C allele (P = .0066), ERCC1 rs735482‐C allele (P = .0204), and ERCC4 rs1799801‐C allele (P = .0286) had lower risk of grade 2‐3 hematologic toxicity. In addition, the presence of G allele of GSTP1 was associated with a significantly lower risk of severe dysphagia (P = .0004).Conclusion: Polymorphisms in ERCC1 and GSTP1 may act as prognostic factors of acute toxicity during treatment with CRT in HNSCC patients.
- 11 April 2019
- Published by Wiley in Head & Neck
- Vol. 41 (8) , 2704-2715
Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum‐based chemoradiotherapy treatment
Background: Platinum‐based chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck squamous‐cell carcinomas (HNSCC), and most patients experience serious toxicities. The aim of this study was to investigate the association between candidate genes involved in radiation/platinum pathways and acute toxicity of CRT to determine the predictive value of these polymorphisms for toxicity.Methods: Thirty‐six selected single nucleotide polymorphisms (SNPs) in 29 genes were genotyped in 110 patients treated with cisplatin‐based CRT. DNA was obtained from blood samples, and SNP analysis was performed using a MassARRAY iPLEX Gold (Sequenom) method.Results: Patients with ERCC1 rs11615‐C allele (P = .0066), ERCC1 rs735482‐C allele (P = .0204), and ERCC4 rs1799801‐C allele (P = .0286) had lower risk of grade 2‐3 hematologic toxicity. In addition, the presence of G allele of GSTP1 was associated with a significantly lower risk of severe dysphagia (P = .0004).Conclusion: Polymorphisms in ERCC1 and GSTP1 may act as prognostic factors of acute toxicity during treatment with CRT in HNSCC patients.
- 1 September 2015
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 90 (9) , 1298-1303
Long Survival and Severe Toxicity Under 5-Fluorouracil–Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS
- 1 September 2015
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 90 (9) , 1298-1303
Long Survival and Severe Toxicity Under 5-Fluorouracil–Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS
- 26 April 2012
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 69 (6) , 1591-1599
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
We are trying to identify predictive factors of high risk of toxicity by analyzing candidate genes in the irinotecan pathways in order to identify useful tools to improve mCRC patient management under real practice conditions.
- 26 April 2012
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 69 (6) , 1591-1599
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
We are trying to identify predictive factors of high risk of toxicity by analyzing candidate genes in the irinotecan pathways in order to identify useful tools to improve mCRC patient management under real practice conditions.
- 7 February 2012
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 13 (3) , 209-217
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale.
- 7 February 2012
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 13 (3) , 209-217
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration
The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale.
- 1 October 2011
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 11 (10) , 1499-1503
Anti-EGFR therapy in first-line colorectal cancer
This Phase II clinical trial investigates the activity and safety of FOLFOX-cetuximab in the first-line treatment of colorectal cancer. This turns out to be an active regimen which allows a high rate of conversion and radical metastectomy. Overall response rate is concordant with those previously reported. The toxicity profile is also similar, and cutaneous toxicity severity seems to be a marker of activity. Retrospectively, the authors analyze the status of KRAS and BRAF in a subgroup of patients, only in 50%. KRAS appears mutated in 37%, and BRAF does not present as mutated in any of the remaining wild-type KRAS patients. KRAS mutation correlates with shorter overall survival and possibly time to progression. The sample is too small to find mutations in BRAF, or to convincingly establish the role of both biomarkers. These data demonstrate an active regimen that is first in line to be confirmed in larger Phase III trials.
- 1 October 2011
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 11 (10) , 1499-1503
Anti-EGFR therapy in first-line colorectal cancer
This Phase II clinical trial investigates the activity and safety of FOLFOX-cetuximab in the first-line treatment of colorectal cancer. This turns out to be an active regimen which allows a high rate of conversion and radical metastectomy. Overall response rate is concordant with those previously reported. The toxicity profile is also similar, and cutaneous toxicity severity seems to be a marker of activity. Retrospectively, the authors analyze the status of KRAS and BRAF in a subgroup of patients, only in 50%. KRAS appears mutated in 37%, and BRAF does not present as mutated in any of the remaining wild-type KRAS patients. KRAS mutation correlates with shorter overall survival and possibly time to progression. The sample is too small to find mutations in BRAF, or to convincingly establish the role of both biomarkers. These data demonstrate an active regimen that is first in line to be confirmed in larger Phase III trials.